Actively Recruiting
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Led by Palo Alto Veterans Institute for Research · Updated on 2025-12-26
12
Participants Needed
1
Research Sites
121 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
CONDITIONS
Official Title
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of hepatocellular carcinoma confirmed by imaging, BCLC stage 0, A, B, or C
- Approval for transarterial Y90 radioembolization by a multidisciplinary tumor board
You will not qualify if you...
- Not eligible for Y90 radioembolization procedure
- Prior surgery or ablation on the tumors planned for Y90 treatment
- Inability to complete required follow-up visits for clinical care or research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304
Actively Recruiting
Research Team
S
Sirish Kishore, MD
CONTACT
L
Luisa Manfredi, MPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here